Patents Assigned to Mediogen Co., Ltd.
  • Patent number: 11857580
    Abstract: The present invention relates to a Lactobacillus strain having antimicrobial activity against Gardnerella vaginalis and Candida albicans, a culture medium of the strain, and a cell-free supernatant of the strain, and to an antimicrobial composition containing the same, a pharmaceutical composition for preventing or treating Gardnerella vaginalis infection or Candida albicans infection containing the same, a pharmaceutical composition for prevention or treatment of vaginitis containing the same, a health functional food for prevention or ameliorating of vaginitis containing the same, and a quasi-drug composition for prevention or amelioration of vaginitis containing the same.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: January 2, 2024
    Assignee: Mediogen Co., Ltd.
    Inventors: Nam-Soo Paek, Chang Ho Kang
  • Patent number: 11738057
    Abstract: Disclosed is a Lactobacillus strain having a blood glucose lowering effect and an antioxidant effect, a culture medium of the strain, and a cell-free supernatant of the strain. Further, a composition for lowering a blood glucose level contains the same. A composition having an antioxidant ability contains the same. The Lactobacillus plantarum MG4229 strain according to the present disclosure has excellent blood glucose lowering activity and antioxidant activity, and has excellent acid tolerance, bile tolerance, auto-aggregation, and adhesion to epithelial cells, and thus is suitable for probiotics, and thus may be used in various ways as a composition for preventing or treating diabetes mellitus or a composition having antioxidant ability.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: August 29, 2023
    Assignee: Mediogen Co., Ltd.
    Inventors: Nam-Soo Paek, Chang Ho Kang
  • Patent number: 11484557
    Abstract: The present invention relates to: human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244; and a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for preventing or treating obesity-related diseases, all of which include the same as an active ingredient. A Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits an anti-obesity activity for inhibiting a lipase enzyme activity, inhibiting preadipocyte differentiation and inhibiting triglyceride accumulation, has an excellent ability to form colonies on the epithelial cells of a digestive tract by means of an excellent auto-aggregation ability, and has resistance to acid and bile, thereby being variously usable as a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for the purpose of treating and preventing obesity-related diseases.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: November 1, 2022
    Assignee: Mediogen Co., Ltd.
    Inventors: Nam Soo Paek, Chang Ho Kang